Ramipril

Generic Name
Ramipril
Brand Names
Altace, Altace HCT
Drug Type
Small Molecule
Chemical Formula
C23H32N2O5
CAS Number
87333-19-5
Unique Ingredient Identifier
L35JN3I7SJ
Background

Ramipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure...

Indication

For the management of mild to severe hypertension. May be used to reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction. To reduce the rate of death, myocardial infarction and stroke in individuals at high ...

Associated Conditions
Cardiovascular Events, Diabetic Nephropathy, Heart Failure, Hearth Failure With Reduced Ejection Fraction (HFrEF), Hypertension, Myocardial Infarction, Nondiabetic proteinuric chronic kidney disease, Stroke, High risk cardiovascular event
Associated Therapies
-
Clinical Trials
Related News

Ramipril Versus Carvedilol in Duchenne and Becker Patients

First Posted Date
2009-01-09
Last Posted Date
2016-01-28
Lead Sponsor
Catholic University, Italy
Target Recruit Count
194
Registration Number
NCT00819845
Locations
🇮🇹

Unione Italiana lotta Distrofia Muscolare, Rome, Italy

Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension

First Posted Date
2008-10-15
Last Posted Date
2011-03-11
Lead Sponsor
Novartis
Target Recruit Count
386
Registration Number
NCT00772577
Locations
🇺🇸

Investigative Site, Houston, Texas, United States

Efficacy Study of Pioglitazone and Ramipril Combination Therapy in Treating Non-diabetic Hypertensive Patients.

First Posted Date
2008-10-10
Last Posted Date
2010-07-05
Lead Sponsor
Takeda
Target Recruit Count
172
Registration Number
NCT00770497

Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension

Phase 3
Completed
Conditions
Hypertension
Interventions
Drug: Ramipril
Drug: Azilsartan medoxomil
First Posted Date
2008-09-26
Last Posted Date
2012-11-15
Lead Sponsor
Takeda
Target Recruit Count
885
Registration Number
NCT00760214

Renin Angiotensin Aldosterone System (RAAS) and Fibrinolysis in Humans: ACEi and PE5i

Not Applicable
Completed
Conditions
Metabolic Syndrome
Interventions
Drug: Ramipril
Drug: Tadalafil
Drug: placebo
First Posted Date
2008-09-10
Last Posted Date
2014-12-18
Lead Sponsor
Vanderbilt University
Target Recruit Count
27
Registration Number
NCT00750308

Prevention of Atrial Fibrillation by Inhibition Conversion Enzyme (ICE) After Radiofrequency Ablation of Atrial Flutter

Phase 3
Terminated
Conditions
Atrial Fibrillation
Atrial Flutter
Interventions
Drug: Ramipril
Drug: Placebo
First Posted Date
2008-08-15
Last Posted Date
2015-07-28
Lead Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Target Recruit Count
198
Registration Number
NCT00736294
Locations
🇫🇷

CHU de Brest, Brest, France

🇫🇷

CHU de Clermont-Ferrand, Clermont Ferrand, France

🇫🇷

CHU de Montpellier, Montpellier, France

and more 5 locations

Study of Inflammation and Oxidative Stress in Persons Undergoing Dialysis

First Posted Date
2008-08-11
Last Posted Date
2013-07-02
Lead Sponsor
Vanderbilt University
Target Recruit Count
19
Registration Number
NCT00732069
Locations
🇺🇸

Vanderbilt University Medical Center, Nashville, Tennessee, United States

PREVENTKD (Prevent Risks by Early interVEntion at Nighttime in Type 1 Diabetes for Kidney Disease)

Phase 3
Terminated
Conditions
Type 1 Diabetes
Interventions
Drug: Placebo
Drug: Ramipril
First Posted Date
2008-08-07
Last Posted Date
2015-03-17
Lead Sponsor
Northwestern University
Target Recruit Count
65
Registration Number
NCT00729365
Locations
🇺🇸

Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

🇺🇸

University of Chicago, Chicago, Illinois, United States

🇺🇸

Rush University Medical Center, Endocrinology Section, Chicago, Illinois, United States

and more 3 locations

Telmisartan Versus Ramipril After Acute Coronary Syndrome

First Posted Date
2008-06-20
Last Posted Date
2008-06-20
Lead Sponsor
Catholic University of the Sacred Heart
Target Recruit Count
50
Registration Number
NCT00702936
Locations
🇮🇹

Catholic University of the Sacred Heart, Rome, Italy

Bioequivalency Study of Ramipril 10 mg Capsules Under Fed Conditions

Not Applicable
Completed
Conditions
Hypertension
First Posted Date
2008-06-20
Last Posted Date
2018-01-23
Lead Sponsor
Roxane Laboratories
Target Recruit Count
39
Registration Number
NCT00702260
Locations
🇺🇸

CEDRA Clinical Research, LLC, Austin, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy